AzTrials
AzTrials

Head and Neck Squamous Cell CarcinomaNCT04740996

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

An observational study of Head and Neck Squamous Cell Carcinoma, run by Shi Yuankai at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This trial is main evaluate the efficacy and safety of pembrolizumab in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥20. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Head and Neck Squamous Cell Carcinoma
What is being tested?
Pembrolizumab
How many people
30 participants
Where
1 siteChina
Study dates
4 Feb 2021to Feb 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with recurrent and/or metastatic head and neck squamous cell carcinoma who are about to receive advanced first-line treatment.

Who may be able to join

  • Voluntarily sign a written informed consent before screening;
  • Male or female, aged ≥18 years old;
  • ECOG physical status score 0-1 points;
  • Head and neck squamous cell carcinoma (HNSCC) confirmed by histology or cytology, the primary site is oral cavity, oropharynx, hypopharynx or larynx;
  • Recurrent and/or metastatic HNSCC without indications for local radical treatment;
  • According to the evaluation criteria for the efficacy of solid tumors (RECIST version 1.1), there is at least one measurable lesion. For lesions that have received radiotherapy in the past, they can only be selected as the disease if there is a clear disease progression 3 months after the end of radiotherapy. Target lesion
Show all 12Show fewer
  • PD-L1 immunohistochemical detection of tumor tissue samples with CPS≥20;
  • The expected survival period exceeds 3 months;
  • The main organs function normally, that is, they meet the following standards:
  • Routine blood test (not receiving blood transfusion, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) within 14 days before the screening examination) : Neutrophils ≥1.5×109/L, platelets ≥100×109/L, hemoglobin ≥90g/L; ii. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ALT and AST≤3×ULN for those without liver metastasis, ALT and AST≤5×ULN for those with liver metastasis; total bilirubin (TBIL)≤ 1.5×ULN (Patients with Gilbert syndrome, ≤3×ULN); iii. Renal function: serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (Ccr) ≥50ml/min; iv. Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT)≤1.5×ULN;
  • Heart echocardiogram: left ventricular ejection fraction (LVEF) ≥50%;
  • Women should agree to use contraceptive measures (such as intrauterine device [IUD], contraceptives or condoms) during the study period and 6 months after the end of the study; the blood pregnancy test is negative within 7 days before the study is enrolled, And must be a non-lactating patient; men should agree to patients who must use contraception during the study period and within 6 months after the end of the study period.

Who cannot join

  • Patients who are suitable for local treatment and are willing to local treatment;
  • Have received systemic chemotherapy, but does not include chemotherapy for locally advanced disease as a part of multimodal treatment (the end of this treatment must be more than 6 months from the first trial drug); Note: Multimodal treatment includes induction chemotherapy, concurrent radiotherapy and chemotherapy and adjuvant chemotherapy.
  • Locally advanced head and neck squamous cell carcinoma multimodal treatment is completed within 6 months of disease progression;
  • Have previously been immunized with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies or any other antibodies or drugs that target T cell co-stimulation or immune checkpoint pathways treatment;
  • Other malignant tumors occurred within 5 years or at the same time during the current period, except for cured cervical carcinoma in situ, non-melanoma skin cancer, or other tumors/cancers that have undergone radical treatment and have no signs of disease for at least 5 years;
  • Received cetuximab treatment within 6 months before the first administration;
Show all 31Show fewer
  • According to the standard of common adverse event term (NCI CTCAEv5.0), peripheral neuropathy has been ≥2 grade;
  • Accompanied by known active central nervous system metastasis (CNS) and/or cancerous meningitis: Subjects with brain metastases who have received previous treatment can participate in the study, provided that they are clinically stable for at least 2 weeks and there are no new or expanded ones Evidence of brain metastases, and steroids were stopped 14 days before study drug administration. Stable brain metastases in this definition should be determined before the first administration of the study drug. Subjects with asymptomatic brain metastases (that is, no neurological symptoms, no corticosteroids, and no lesions> 1.5 cm) can participate, but they need to have regular brain imaging examinations as the disease site;
  • Subjects who have not recovered from any acute effects of previous surgery, chemotherapy or radiotherapy, that is, subjects who have not fallen to ≤1 (NCI CTCAEv5.0) (except for hair loss). If the nutritional status is stable, allow the chronic late toxicity (pharyngeal/laryngo toxicity, dry mouth, abnormal speech, swallowing, etc.) from previous radiotherapy and/or surgery;
  • Any component of the studied drug or preparation has caused severe allergic reactions, including known severe allergic reactions to other monoclonal antibodies (NCI CTCAEv5.0≥3);
  • Have received anti-tumor drug therapy (such as chemotherapy, hormone therapy, immunotherapy, antibody therapy, radiotherapy, etc.) 4 weeks or 4 weeks before the first administration, except for palliative radiotherapy for bones to relieve pain;
  • Chinese herbal medicines or proprietary Chinese medicines that have received anti-tumor treatment ≤1 week before the first administration;
  • Have received major surgery within 4 weeks before the first administration or are expected to undergo major surgery during the study period;
  • Immunosuppressive drugs need to be used 2 weeks before the first administration or within 2 weeks or during the study period, except for the following conditions:
  • Intranasal, inhaled, topical steroid or topical steroid injection (such as intra-articular injection);
  • Physiological dose of systemic corticosteroids (≤10mg/day prednisone or equivalent dose);
  • Short-term (≤7 days) use of steroids to prevent or treat non-autoimmune allergies Sexual disease
  • Subjects who are known to have active or have a history of autoimmune diseases that are likely to relapse (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, Patients with multiple sclerosis, vasculitis, glomerulitis, etc.), or high-risk (such as receiving an organ transplant and requiring immunotherapy). However, the following patients are allowed to join the group: patients with type I diabetes who are in stable condition after using a fixed dose of insulin; autoimmune hypothyroidism who only needs hormone replacement therapy; skin diseases that do not require systemic treatment (such as eczema, which occupies body surface Less than 10% of skin rashes, psoriasis without ophthalmological symptoms, etc.);
  • Subjects with known history of interstitial lung disease, history of non-infectious pneumonia, or high suspicion of interstitial lung disease; subjects who have previously had drug-induced or radiation non-infectious pneumonia but asymptomatic are allowed to enter group;
  • History of infection with human immunodeficiency virus (positive HIV test), or other acquired or congenital immunodeficiency diseases, or history of organ transplantation, or history of stem cell transplantation;
  • At the time of screening, the hepatitis B or C virology test meets any of the following:
  • HBsAg is positive and the titer of hepatitis B virus deoxyribonucleic acid (HBV DNA) in peripheral blood is ≥104 copies/ml or ≥2000 IU/ml;
  • HCV antibody is positive, and HCV-RNA is higher than the detection limit of the analysis method;
  • Within 2 weeks or 2 weeks before the first administration, the subject has an active infection or uncontrollable infection that requires systemic treatment (except simple urinary tract infection or upper respiratory tract infection);
  • Live virus vaccine has been vaccinated within 4 weeks before the first dose. Allow seasonal influenza vaccination without live virus;
  • Serous effusion (such as pleural effusion and ascites) with clinical symptoms that require clinical intervention or stable time less than 4 weeks;
  • Known to be accompanied by serious medical diseases, such as cardiac dysfunction of grade III and above (New York Heart Association [NYHA]), cardiovascular diseases such as ischemic heart disease (such as myocardial infarction or angina), or the first administration A history of myocardial infarction within the first 3 months, poorly controlled diabetes (fasting blood glucose ≥10mmol/L) or poorly controlled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg) after drug treatment;
  • Medical or psychiatric history or laboratory abnormality history that may interfere with the interpretation of results;
  • The subject is currently enrolled in another research device or research drug study, or the time away from stopping other research drugs or research devices is less than or equal to 4 weeks;
  • The subject is known to be addicted to alcohol or drugs;
  • The researcher believes that the subject has other conditions that may affect its compliance with the protocol and the evaluation of the research indicators, and it is not suitable for the subjects to participate in the research.

Trial locations and contacts

1 site in 1 country.

Yuankai Shi, MD contact

+86-10-87788293

syuankaipumc@126.com

China1 site, 1 recruiting

  • Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Beijing

    Yuankai Shi

    Recruiting

Other trials in China

About this study

Official title: A Prospective Registration Study of Pembrolizumab in the First Line Therapy for PD-L1 CPS≥20 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in China

This trial is main evaluate the efficacy and safety of pembrolizumab in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥20.

Read the detailed description

This trial is a single-center, prospective phase II clinical study, which mainly evaluates the efficacy and safety of first-line treatment with pembrolizumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20 in China.

Being tested
Pembrolizumab
Keywords
Head and Neck Cancer, immune therapy, Pembrolizumab
Medical subject headings
Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PembrolizumabDrug

    Also called keytruda

    Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective response rate (ORR)

    To evaluate the objective response rate (ORR, RECIST standard 1.1 evaluation) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20

    Measured: 1 year

  2. survival time (OS)

    To evaluate the survival time (OS) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20

    Measured: 1year

Secondary outcomes (4)

  1. objective response rate(ORR)

    To evaluate the objective response rate of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20 (ORR, iRECIST standard evaluation)

    Measured: 1 year

  2. disease control rate (DCR)

    To evaluate the disease control rate (DCR) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20

    Measured: 1 year

  3. duration of response (DOR)

    To evaluate the duration of response (DOR) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS ≥ 20

    Measured: 1 year

  4. progression-free survival (PFS, PFS2)

    To evaluate the progression-free survival (PFS, PFS2) of patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS ≥ 20 in the first-line treatment of Pembrolizumab;

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2021
  2. Study start4 Feb 2021
  3. Primary completionFeb 2024 (estimated)
  4. Study completionFeb 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04740996
Sponsor's protocol ID
NCT123
Status last verified
Feb 2022
First submitted
2 Feb 2021
Last updated
7 Feb 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Head and Neck Squamous Cell Carcinoma, run by Shi Yuankai at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Yuankai Shi, MD (+86-10-87788293, syuankaipumc@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective response rate (ORR) (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04740996.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Feb 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in